Egetis Gains Key U.S. Patent Protection for Emcitate in MCT8 Deficiency

An announcement from Egetis Therapeutics AB ( (SE:EGTX) ) is now available.

Egetis Therapeutics has secured a U.S. patent covering pharmaceutical compositions of tiratricol for treating MCT8 deficiency, including methods of use, dosing regimens and specific excipient combinations. The patent, which runs to 2045 and is expected to be Orange Book-listable, strengthens protection around Emcitate and would complement anticipated seven-year orphan drug exclusivity if the therapy is approved in the U.S.

The company plans to pursue corresponding patent protection in key international markets, including Europe and Japan, further consolidating its intellectual property around Emcitate. With Emcitate already approved in the EU and its U.S. New Drug Application under Priority Review with a PDUFA date of September 28, 2026, the new patent enhances Egetis’ strategic position in the rare disease space and could support long-term value for patients and investors in the MCT8 deficiency market.

More about Egetis Therapeutics AB

Egetis Therapeutics AB is an integrated pharmaceutical company focused on late-stage development and commercialization of treatments for serious diseases with significant unmet medical needs in the orphan drug segment. Its lead product, Emcitate (tiratricol), is the first approved treatment for MCT8 deficiency in the EU, while its U.S. approval is under FDA Priority Review, and the company is also developing Aladote for liver injury from paracetamol overdose, though that program is currently parked.

Average Trading Volume: 847,520

Technical Sentiment Signal: Buy

Current Market Cap: SEK2.22B

See more data about EGTX stock on TipRanks’ Stock Analysis page.